Novo Nordisk A/S $NVO Stock Holdings Boosted by Pinnacle Wealth Planning Services Inc.

Pinnacle Wealth Planning Services Inc. boosted its position in Novo Nordisk A/S (NYSE:NVO) by 22.7% during the 2nd quarter, HoldingsChannel reports. The firm owned 18,790 shares of the company’s stock after buying an additional 3,477 shares during the quarter. Pinnacle Wealth Planning Services Inc.’s holdings in Novo Nordisk A/S were worth $1,297,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Revolve Wealth Partners LLC raised its holdings in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares during the last quarter. Kingsview Wealth Management LLC grew its holdings in Novo Nordisk A/S by 9.3% in the 1st quarter. Kingsview Wealth Management LLC now owns 5,404 shares of the company’s stock worth $375,000 after buying an additional 461 shares in the last quarter. Kestra Private Wealth Services LLC increased its position in Novo Nordisk A/S by 22.4% in the 1st quarter. Kestra Private Wealth Services LLC now owns 59,531 shares of the company’s stock valued at $4,134,000 after acquiring an additional 10,891 shares during the period. OneAscent Financial Services LLC raised its stake in Novo Nordisk A/S by 75.7% during the 1st quarter. OneAscent Financial Services LLC now owns 9,306 shares of the company’s stock valued at $644,000 after acquiring an additional 4,010 shares in the last quarter. Finally, J.W. Cole Advisors Inc. boosted its position in Novo Nordisk A/S by 58.3% during the 1st quarter. J.W. Cole Advisors Inc. now owns 16,266 shares of the company’s stock worth $1,129,000 after acquiring an additional 5,989 shares during the period. 11.54% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Barclays reissued an “equal weight” rating on shares of Novo Nordisk A/S in a report on Wednesday, July 30th. Berenberg Bank raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Wednesday, September 17th. HSBC set a $70.00 price target on Novo Nordisk A/S in a research report on Wednesday, October 1st. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Finally, Morgan Stanley lowered shares of Novo Nordisk A/S from an “overweight” rating to an “underweight” rating and reduced their price objective for the company from $59.00 to $47.00 in a research report on Monday, September 29th. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $59.20.

Novo Nordisk A/S Trading Up 0.5%

NYSE:NVO opened at $48.52 on Tuesday. The stock’s 50-day moving average is $54.44 and its two-hundred day moving average is $60.85. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $112.52. The stock has a market cap of $216.63 billion, a PE ratio of 13.33, a price-to-earnings-growth ratio of 2.33 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. The company had revenue of $11.74 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.